(function(){
			var content_array=["<p><strong>Notes to Editors<\/strong><\/p>\r\n<p>For more information on predictive biomarkers in colorectal cancer, please visit: <a rel=\"nofollow\" href=\"http:\/\/www.globalcancernews.com\" target=\"_blank\">http:\/\/www.globalcancernews.com<\/a>.<\/p>\r\n<p><strong>About Sysmex Inostics<\/strong>&nbsp;<\/p>\r\n<p>Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection utilizing highly sensitive technologies such as Plasma-Sequencing and BEAMing. With BEAMing being one of the most sensitive and quantitative technologies available today for the detection of tumor specific somatic mutations in blood samples, Sysmex Inostics' BEAMing services are readily available to support clinical trials and research in oncology. Furthermore, Sysmex Inostics companion diagnostics (CDx) team offers services for the development of non-invasive plasma DNA based IVD tests supported by a growing network of partners to cover the entire IVD development process. In addition, BEAMing tests (OncoBEAM) are available through a CLIA certified laboratory for routine clinical analysis.<\/p>\r\n<p>Sysmex Inostics' headquarters are located in Hamburg, Germany and Sysmex Inostics' Clinical Laboratory is located in Baltimore, Maryland. For more information on OncoBEAM blood testing and the BEAMing technology refer to <a rel=\"nofollow\" href=\"http:\/\/www.sysmex-inostics.com\/\" target=\"_blank\">http:\/\/www.sysmex-inostics.com<\/a> or email <a rel=\"nofollow\" href=\"mailto:info@sysmex-inostics.com\" target=\"_blank\">info@sysmex-inostics.com<\/a>.<\/p>\r\n<p><strong>About Erbitux<\/strong>&nbsp;<\/p>\r\n<p>Erbitux&reg; is a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.<\/p>\r\n<p>The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.<\/p>\r\n<p>Erbitux has already obtained market authorization in over 90 countries for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN).<\/p>\r\n<p>Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.<\/p>\r\n<p><strong>About Merck<\/strong>&nbsp;<\/p>\r\n<p>All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to <a rel=\"nofollow\" href=\"http:\/\/www.merckgroup.com\/subscribe\" target=\"_blank\">http:\/\/www.merckgroup.com\/subscribe<\/a> to register online, change your selection or discontinue this service.<\/p>\r\n<p>Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of EUR 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.<\/p>"];
			$("#dvExtra").html(content_array[0]);})();